Literature DB >> 2428759

Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney.

E Oosterwijk, D J Ruiter, P J Hoedemaeker, E K Pauwels, U Jonas, J Zwartendijk, S O Warnaar.   

Abstract

This report describes a monoclonal antibody designated G 250, subclass IgGl, that recognizes an antigen preferentially expressed on cell membranes of renal-cell carcinoma cells (RCC) and not expressed in normal proximal tubular epithelium. G 250 antibody reacted with 46 of 47 primary RCC, with 7 of 8 RCC metastases and with a few other malignant tumors. The staining pattern of G 250 differs from that of other RCC-related antibodies described. Preliminary experiments show that this antibody can be used to visualize RCC xenografts in nude mice by immunoscintigraphy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428759     DOI: 10.1002/ijc.2910380406

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  88 in total

1.  Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).

Authors:  Peter Mulders; I Bleumer; F Debruyne; E Oosterwijk
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

2.  [Renal cell carcinoma associated proteins. Isolation, cloning and immunogenicity evaluation].

Authors:  A Haferkamp; M Hohenfellner; R Hautmann; M Zöller
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 3.  G250: a carbonic anhydrase IX monoclonal antibody.

Authors:  John S Lam; Allan J Pantuck; Arie S Belldegrun; Robert A Figlin
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

Review 4.  Novel approaches in the therapy of metastatic renal cell carcinoma.

Authors:  John S Lam; John T Leppert; Arie S Belldegrun; Robert A Figlin
Journal:  World J Urol       Date:  2005-04-05       Impact factor: 4.226

Review 5.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

6.  Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.

Authors:  Won K Han; Anwar Alinani; Chin-Lee Wu; Dror Michaelson; Massimo Loda; Francis J McGovern; Ravi Thadhani; Joseph V Bonventre
Journal:  J Am Soc Nephrol       Date:  2005-03-02       Impact factor: 10.121

7.  Advances in Anti-Cancer Drug Development Targeting Carbonic Anhydrase IX and XII.

Authors:  Mam Y Mboge; Robert McKenna; Susan C Frost
Journal:  Top Anticancer Res       Date:  2015

8.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Authors:  Cor Hj Lamers; Stefan Sleijfer; Sabine van Steenbergen; Pascal van Elzakker; Brigitte van Krimpen; Corrien Groot; Arnold Vulto; Michael den Bakker; Egbert Oosterwijk; Reno Debets; Jan W Gratama
Journal:  Mol Ther       Date:  2013-02-19       Impact factor: 11.454

9.  Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.

Authors:  Chen Xu; Agnes Lo; Anuradha Yammanuru; Aimee St Clair Tallarico; Kristen Brady; Akikazu Murakami; Natasha Barteneva; Quan Zhu; Wayne A Marasco
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

10.  The most recently discovered carbonic anhydrase, CA XV, is expressed in the thick ascending limb of Henle and in the collecting ducts of mouse kidney.

Authors:  Sina Saari; Mika Hilvo; Peiwen Pan; Gerolf Gros; Nina Hanke; Abdul Waheed; William S Sly; Seppo Parkkila
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.